CTLA4 and colitis: The type of fatal irAEs varied depending on the regimen; the most common fatal irAE with anti-CTLA-4 treatment was colitis (70%), whereas the most common fatal irAEs with anti-PD-1/anti-PD-L1 treatment were pneumonitis (35%), hepatitis (22%), and neurotoxicity (15%).